SURUNKALI LIMFOLEYKOZDA SITOMORFOLOGIK O’ZGARISHLAR
Keywords:
Kalit so’zlar: surunkali limfoleykoz, sitomorfologik o’zgarishlar, limfotsitlar, suyak ko’migi, sitogenetik tahlil, tashxis, prognoz.Abstract
Annotatsiya. Maqolada surunkali limfoleykoz (SLL) bilan kasallangan bemorlarda aniqlanadigan sitomorfologik o‘zgarishlarning o‘ziga xos jihatlari o‘rganilgan. Tadqiqot davomida bemorlarning periferik qon va suyak ko‘migi surtmalari morfologik hamda sitogenetik tahlil asosida tekshirildi. Olingan natijalar SLLda limfotsitlarning yadro va sitoplazma tuzilishidagi o‘zgarishlar, pro- va paralimfotsitlarning nisbati, shuningdek 13q14 delesiyasi va 12-xromosoma trisomiyasi kabi genetik buzilishlar kasallikning klinik kechishi va prognozi bilan chambarchas bog‘liq ekanligini ko‘rsatdi. Ushbu o‘zgarishlarni kompleks baholash surunkali limfoleykozning erta tashxisi, prognozini aniqlash va individual davolash strategiyasini ishlab chiqishda muhim ahamiyatga ega.
References
1. Хасанов Ш.Ш., Бекназарова Н.Х. Gematologiya asoslari. – Toshkent: “Fan”, 2020. – 312 b.
2. Kipps T.J., Stevenson F.K., Wu C.J., et al. Chronic lymphocytic leukemia. New England Journal of Medicine. 2017; 376(15): 1457–1470.
3. Oscier D., Dearden C., Eren E., et al. Morphology and immunophenotype of CLL in relation to genetic abnormalities. Blood Reviews. 2020; 40: 100636.
4. Döhner H., Stilgenbauer S., Benner A., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. Leukemia. 2019; 33(5): 1028–1038.
5. Hallek M., Al-Sawaf O. Chronic lymphocytic leukemia: 2021 update on diagnosis, risk stratification and treatment. American Journal of Hematology. 2021; 96(5): 508–526.
6. WHO Classification of Tumours Editorial Board. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 5th edition. Lyon: IARC; 2022.
7. Shanafelt T.D., Ghia P., Lanasa M.C., et al. Prognostic factors in chronic lymphocytic leukemia: biological and clinical markers. Clinical Lymphoma, Myeloma & Leukemia. 2019; 19(1): 13–25.
8. Farmonqulov X.Q. Leykozlar va limfomalar. // Toshkent 2012 y, S-217-220.
